Tetrahydrocannabiphorol
Viewing r1 — May 11, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
THCP (tetrahydrocannabiphorol) is a cannabinoid of the dibenzopyran class. It resembles Δ9-THC but carries a longer carbon chain that dramatically increases its potency. It activates cannabinoid receptors roughly 33 times more strongly than THC,[1] producing intense sedation and a powerful cannabis-like high.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Δ9-THC, Δ8-THC, HHC +2 moreΔ9-THC, Δ8-THC, HHC, HHCP, synthetic cannabinoids show less
THCP was first isolated in 2019 by Italian researchers profiling the FM2 medicinal cannabis strain[1] — a trace compound nobody had previously noticed. Within three years, synthetically produced THCP appeared in commercial vape cartridges and edibles, often as an unregulated replacement for newly scheduled cannabinoids.[2][3] It circulates today in unregulated markets across Europe and North America.
Subjective effects include heavy sedation, intense euphoria, appetite stimulation, altered time perception, and marked short-term memory loss. The experience resembles cannabis but amplified — heavier, more disorienting, and capable of overwhelming cognitive function at doses where THC would cause only mild intoxication.[2] Anxiety, paranoia, and confusion are common unsought effects, particularly at higher doses.
THCP carries elevated dependence and acute toxicity risk relative to THC. It drives cannabinoid receptors to their maximum — unlike THC, which has a built-in ceiling — predicting faster tolerance and a lower threshold for severe reactions including seizure.[4][5] No controlled human data exist; all risk estimates come from animal studies and structural analogy to more dangerous synthetic cannabinoids.
History[edit]
History
Discovery
THCP was first identified in December 2019 by Cinzia Citti, Pasquale Linciano, Giuseppe Cannazza, and colleagues, who found it in trace quantities in Italy's FM2 medicinal cannabis variety.[1] They used high-resolution mass spectrometry and confirmed the find by synthesizing a reference standard from CBD. A related compound, cannabidiphorol (CBDP), was isolated at the same time.[1]
Market emergence
The discovery mattered because it showed the cannabis plant itself could produce cannabinoids at potency levels previously associated only with synthetic research chemicals.[4] By 2022–2023, synthetically produced THCP appeared in commercial vape cartridges and edibles across Europe and North America, typically as an unregulated replacement after related compounds were banned.[2][3] In Sweden, it filled the market gap left when HHC and HHC-P were classified as narcotics in July 2023.[6]
The suffix "phorol" in THCP's name comes from its seven-carbon (heptyl) side chain, following the naming convention for cannabinoid homologs. THCP belongs to a broader phorol family including CBDP, CBGP, and the hydrogenated structural analog HHCP.
Chemistry[edit]
Chemistry
Structure and classification
THCP belongs to the dibenzopyran family — the same structural class as Δ9-THC.[1] The molecule differs from THC in one way: a seven-carbon chain at the position where THC has a five-carbon chain.[1]
| Molecular formula | C₂₃H₃₄O₂ |
| Molecular weight | 342.5 g/mol |
Longer carbon chains increase cannabinoid receptor potency, and seven carbons sits near the peak of that relationship.[4] THCP occurs naturally only in trace quantities in cannabis plants;[7] all commercial products are produced by chemical synthesis, and laboratory testing has detected unlabeled synthesis byproducts — including Δ8-THCP isomers — in commercial products.[3]
Pharmacology[edit]
Pharmacology
Mechanism of action
THCP is a full agonist at cannabinoid receptors — a critical distinction from Δ9-THC, which is a partial agonist.[5] THC hits a natural ceiling on receptor activation regardless of dose; THCP has no such ceiling and drives those receptors to their maximum.[5][4] THCP also binds CB2 receptors with high affinity, which may contribute anti-inflammatory effects, though no CB2-specific functional data have been published.[1]
In vivo effects
In mouse studies, THCP produced all four classic cannabinoid effects — reduced movement, pain suppression, immobility, and lowered body temperature — at doses where Δ9-THC was inactive or less effective.[1] No human or primate dose-response data exist.safety citation needed
Pharmacokinetics
No human pharmacokinetic studies for THCP have been published. Based on structural similarity to THC, it is expected to absorb rapidly when inhaled and slowly when swallowed, with liver enzymes breaking it down at multiple positions.[8] Its longer side chain predicts greater fat solubility than THC, likely resulting in more accumulation in body fat and a longer time to clear.inferred
Neuroscience[edit]
Neuroscience
Where it acts
CB1 receptors — the brain's main cannabinoid target — are concentrated in regions controlling memory (hippocampus), movement (basal ganglia), and judgment (prefrontal cortex). THCP's high potency predicts more pronounced effects in all these areas at lower doses than THC.inferred Low-level CB1 stimulation in the amygdala tends to reduce anxiety; high-level activation provokes it — consistent with the dose-dependent shift from calm to paranoia that users report.[2]
Why it matters
The endocannabinoid system fine-tunes brain activity on demand. Exogenous cannabinoids like THCP override this by providing continuous receptor activation where the brain expects precise, moment-to-moment signals. Over time, the brain compensates by reducing receptor numbers and sensitivity — the mechanism underlying tolerance.[9]
THCP's full agonism may also produce stronger activation of the brain's mesolimbic pathway than THC.inferred CB1 receptors on inhibitory neurons in that circuit hold dopamine release in check; full agonism lifts that brake more completely than partial agonism, potentially driving stronger reinforcement and greater dependence risk.inferred
- Does THCP cross the blood-brain barrier more readily than THC? Greater fat solubility generally enhances brain penetration, but the relationship is complex and THCP-specific data are absent.
- What are the neurocognitive consequences of chronic THCP use? High-potency cannabis is associated with reduced hippocampal volume and altered brain connectivity — whether THCP's higher potency amplifies these effects is unknown.
- Does THCP affect the developing brain differently from THC? Adolescent exposure to potent CB1 agonists disrupts normal brain maturation processes,[10] and the developmental toxicity threshold for THCP has not been investigated.
Subjective Effects[edit]
Subjective Effects
The THCP experience is a heavier, more consuming version of cannabis intoxication. Full cannabinoid receptor activation removes the natural ceiling that THC respects, meaning the experience can escalate past comfortable control — into deep sedation, significant cognitive disruption, and emotional lability.[2]
Within the cannabinoid class, THCP sits pharmacologically closer to potent synthetic cannabinoids like JWH-018 than to conventional cannabis — despite being a natural phytocannabinoid. Users describe effects that can exceed familiar cannabis bounds, particularly in sedation depth and cognitive disruption.[2]
Effect Grid
Pronounced euphoria and sedation define the common-dose experience. Cognitive impairment becomes clear — short-term memory is disrupted, focus is suppressed, and thought tempo decelerates noticeably. Time distortion is prominent, with minutes feeling substantially elongated. Appetite enhancement is strong. Emotional responses are heightened, and humor enhancement is typical.
Body heaviness and muscle relaxation are substantial. Dry mouth is likely. Heart rate perception changes may be noticed. Motor control is meaningfully impaired — coordination tasks become clumsy. A warm, spreading body high pervades.
Anxiety is possible in predisposed individuals or unfamiliar settings. Functional impairment is significant — driving and complex tasks are unsafe. Duration of commitment is several hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Taste enhancement · Peripheral vision distortion · Auditory distortion · Color alteration · Visual acuity suppression · Visual haze / noise · Peripheral misidentification · Auditory misinterpretation · Light sensitivity · Vestibular distortion · Visual breathing · Olfactory enhancement · After-images · Tracers · Visual drifting
Touch enhancement · Taste enhancement · Peripheral vision distortion · Auditory distortion · Color alteration · Visual acuity suppression · Visual haze / noise · Peripheral misidentification · Auditory misinterpretation · Light sensitivity · Vestibular distortion · Visual breathing · Olfactory enhancement · After-images · Tracers · Visual drifting
Bodily heaviness · Heart rate perception changes · Muscle relaxation · Pain suppression · Appetite enhancement · Dehydration sensation · Dizziness · Laughter fits · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Temperature dysregulation · Body schema distortion · Nausea suppression · Pupil dilation · Breathing alteration · Constipation · Headache · Insomnia · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Sexual arousal suppression · Muscle tension · Restlessness · Stimulation · Tingling / electric sensations · Trembling · Vibrations / buzzing · Vomiting · Bodily dissociation
Pain suppression · Appetite enhancement · Dehydration sensation · Dizziness · Laughter fits · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Body schema distortion · Nausea suppression · Pupil dilation · Breathing alteration · Constipation · Headache · Insomnia · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Sexual arousal suppression · Muscle tension · Restlessness · Stimulation · Tingling / electric sensations · Trembling · Vibrations / buzzing · Vomiting · Bodily dissociation
Memory fragmentation · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive euphoria · Confusion · Immersion enhancement · Information processing suppression · Introspection enhancement · Novelty enhancement · Openness enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Motivation suppression · Cognitive dysphoria · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Compulsive redosing urge · Creativity suppression · Amnesia · Delirium · Delusions
Analysis suppression · Cognitive euphoria · Confusion · Immersion enhancement · Information processing suppression · Introspection enhancement · Novelty enhancement · Openness enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Motivation suppression · Cognitive dysphoria · Conceptual thinking · Creativity enhancement · Increased nature relatedness · Language suppression · Multiple thought streams · Pattern recognition enhancement · Thought deceleration · Thought loops · Compulsive redosing urge · Creativity suppression · Amnesia · Delirium · Delusions
Anxiety suppression · Emotional lability · Dysphoria · Emotional suppression · Empathy enhancement · Irritability · Simultaneous emotions · Anhedonia · Empathy suppression · Mania
Emotional suppression · Empathy enhancement · Irritability · Simultaneous emotions · Anhedonia · Empathy suppression
Depersonalization · Derealization · Sociability enhancement · Compulsive behavior reduction · Sociability suppression · Social connection · Social disconnection · Trust enhancement · Communication enhancement · Flow state · Ego inflation · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Sociability suppression · Social connection · Social disconnection · Trust enhancement · Communication enhancement · Flow state · Ego inflation · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Timeline
Delayed onset typical of oral cannabinoids. A subtle shift in mood or body awareness emerges 30–90 minutes after ingestion. The slow onset increases redosing risk.
Gradual intensification over 30–60 minutes. Euphoria, body warmth, and cognitive slowing build steadily. First-pass metabolism may produce an active 11-OH metabolite contributing to intensity.
Full intoxication — potentially more intense than the vaporized route due to 11-OH metabolite contribution. Sedation, cognitive impairment, and time distortion reach maximum. Anxiety risk elevated.
Extended plateau characteristic of oral cannabinoid administration. Effects remain strong and sustained. Body heaviness and appetite stimulation persist at near-peak levels.
Slow decline over several hours. Sedation and cognitive fog recede gradually. Motor coordination returns but may remain subtly impaired.
Prolonged residual effects including mild sedation, cognitive haze, and appetite changes. Next-day grogginess is possible, particularly at higher doses.
⚠ Do not drive or operate heavy machinery for at least 12 hours after oral ingestion, or longer if any impairment is perceived.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 3 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · Δ8-THC · HHC
Toxicity
No lethal dose data for THCP have been published in any species. Based on its full agonist profile and potency, severe adverse effects are expected to occur at much lower doses than with THC.safety citation needed
Acute toxicity
Full CB1 agonists with comparable potency — including synthetic cannabinoids of the JWH and HU series — have been associated with seizures, loss of consciousness, and coma.[4] Rapid heart rate is a class effect of potent CB1 activation; dangerous heart rhythm disturbances are possible at high doses or in predisposed individuals. No THCP-specific case reports have been published.
Product contamination
Laboratory analysis of a commercial THCP vape cartridge found unlabeled impurities including synthesis byproducts and Δ8-THCP isomers.[3] The toxicity of these byproducts is unknown, and labeled potency may not match actual THCP content.[3]
Psychological Risks
Acute psychotic symptoms — hallucinations, paranoia, thought disorganization — occur in roughly 0.47% of cannabis users over a lifetime, with substantially elevated rates in young users, high-potency preparation users, and those with pre-existing psychiatric vulnerability.[11] THCP's markedly higher potency suggests these effects occur at a lower threshold and with greater severity.
High-potency cannabis is associated with worse mental health outcomes in adolescents, including higher rates of anxiety, depression, and psychotic experiences.[10] THCP sits at the extreme end of this potency spectrum. No THCP-specific data on long-term psychiatric effects exist.
Tolerance & Dependence
Chronic CB1 agonist exposure causes receptors to downregulate and desensitize, producing behavioral tolerance.[9] THCP's full agonism may drive tolerance faster and more completely than THC — a pattern seen with comparably potent synthetic cannabinoids.inferred Cannabis use disorder develops in roughly 9% of all users and up to 17% of those who begin in adolescence;citation needed THCP's full agonism and higher potency predict elevated abuse liability.
Cannabis withdrawal brings irritability, anxiety, sleep disturbance, reduced appetite, and low mood — beginning 1–3 days after cessation and peaking around days 2–6. No pharmacotherapy is currently approved.[12] THCP-specific withdrawal has not been characterized.
Drug Interactions
No THCP-specific interaction data exist; all information is inferred from THC pharmacology.[8][13] THCP is expected to use the same liver enzymes as THC and may impair those enzymes, causing other drugs to accumulate to dangerous levels. Warfarin, tacrolimus, and cyclosporine are particularly risky — small increases in their blood levels carry serious consequences.
Combining THCP with alcohol, benzodiazepines, or opioids adds sedation and respiratory depression. The opioid combination is especially concerning — cannabinoid-opioid receptor crosstalk can mask worsening breathing. Chronic cannabinoid use is associated with increased anesthetic requirements,[9] and anesthesia providers should be informed of THCP use.
All interaction severities are uncharacterized for THCP specifically.safety citation needed
Contraindications
No THCP-specific contraindication data exist. The following are inferred from full CB1 agonist pharmacology.
Absolute contraindications:
- Personal or family history of psychotic disorders — CB1 agonism precipitates and worsens psychotic symptoms; full agonism at THCP's potency amplifies this risk[11]
- Unstable heart conditions — rapid heart rate and blood pressure effects of potent CB1 agonism pose risk in the context of rhythm disorders, recent heart attack, or heart failuresafety citation needed
Relative contraindications:
- Bipolar disorder — CB1 agonism may trigger manic episodes
- Pregnancy and breastfeeding — cannabinoids cross the placenta and enter breast milk; high-potency CB1 agonism poses unknown developmental risk
- Adolescence — developing endocannabinoid systems are vulnerable to disruption by potent exogenous agonists[10]
- Medications with narrow safety margins processed by CYP2C9 or CYP3A4 (warfarin, tacrolimus, cyclosporine)[13]
- History of cannabis use disorder — full agonism and higher potency predict stronger reinforcement
- Liver impairment — reduced metabolism may increase THCP exposure and prolong effectsinferred
All contraindications are class-level inferences.
Harm Reduction[edit]
Harm Reduction
Forms & Identification
Commercial THCP is entirely synthetic — produced in a lab, not extracted from cannabis plants. Laboratory analysis has confirmed that commercial products may contain unlabeled impurities whose toxicity is unknown.[3]
Standard cannabis reagent testing cannot identify these contaminants. Labeled potency may not reflect actual THCP content. Treat every new product or batch as unknown potency.
Set & Setting
THCP's high potency creates a narrow margin between desired effects and overwhelming intoxication. A calm, familiar, private environment with a sober companion present significantly reduces the risk of anxiety escalation and disorientation — especially for those without prior experience with the compound.
Avoid unfamiliar, public, or socially demanding settings. Even moderate doses produce cognitive impairment and heavy sedation that can make navigation, communication, and self-care difficult.
Guidelines
- Test every product. Third-party laboratory certificates of analysis (COAs) are the minimum standard — products without them should be treated as unverified.
- Start with the lowest available dose and wait. Oral THCP has delayed and variable onset; redosing before full effects appear is the most common path to accidental overdose with potent edibles.
- Inhaled THCP allows better dose control than oral preparations, but onset is rapid and the window between desired effect and overwhelming intoxication is narrow.
- Do not use alone until individual response is well established. A sober companion should be present for first experiences.
- Do not drive or operate machinery. THCP produces substantial cognitive and motor impairment.
- Keep sessions infrequent. Full CB1 agonism predicts faster tolerance development and potentially greater abuse liability than THC.
Aftercare & Integration
THCP's potency can produce experiences that feel qualitatively different from ordinary cannabis — intense sedation, cognitive disruption, and anxiety or paranoia that may linger after acute effects resolve. Allow a full recovery day after use, prioritizing sleep, hydration, and light nutrition.
If the experience produced significant anxiety, paranoia, or depersonalization, processing with a trusted person can help contextualize what happened. Persistent anxiety, mood changes, or perceptual disturbances lasting more than a few days warrant consultation with a mental health professional.
Recovery & Support
Signs of problematic use include escalating doses, difficulty controlling frequency, continued use despite negative consequences, and withdrawal symptoms (irritability, anxiety, sleep disruption, appetite suppression) upon cessation.
Cannabis use disorder is a recognized clinical condition with effective treatment options including cognitive behavioral therapy, motivational enhancement therapy, and contingency management. No pharmacotherapy is currently approved for cannabis withdrawal, but clinical support can substantially ease the process. Resources include the SAMHSA National Helpline (1-800-662-4357), Marijuana Anonymous (marijuana-anonymous.org), and local addiction medicine providers.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable but manageable effects include anxiety, rapid heartbeat, nausea, and disorientation. Seek immediate help if any of the following occur: seizure activity, loss of consciousness or unresponsiveness, chest pain, severe breathing difficulty, or psychotic symptoms (complete disconnection from reality, self-harm risk, extreme agitation unresponsive to reassurance).
Immediate steps:
- 1. Call emergency services if the person is unconscious, seizing, or showing signs of psychosis with self-harm risk.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not leave the person alone. Speak calmly and reassuringly.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others.
- 5. Do not induce vomiting.
- 6. Remove stimulating inputs — lower lights, reduce noise.
What to tell the dispatcher: State the substance (THCP, a potent cannabinoid), the approximate amount and time consumed, the route (inhaled or oral), and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help for drug-related emergencies.
No reversal agent exists for cannabinoid intoxication. Treatment is supportive.
Legal Status[edit]
Legal Status
THCP entered commercial markets before regulators could respond, and its legal status continues to evolve rapidly across jurisdictions.[6][14]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled; legal gray zone | Potentially legal under the 2018 Farm Bill if derived from hemp with less than 0.3% Δ9-THC by dry weight. Congress revised the Farm Bill definition in November 2025 to encompass total THC (not only Δ9-THC), effective November 2026, which may substantially affect THCP's federal status[15] |
| United States (state-level) | Banned in multiple states | As of mid-2025, Alaska, Delaware, Hawaii, Idaho, Mississippi, Montana, New York, North Dakota, Rhode Island, Vermont, Washington, and West Virginia have enacted bans or analog scheduling covering THCP[15] |
| United Kingdom | Likely Class B (Misuse of Drugs Act 1971) | Controlled under analogue provisions covering psychoactive cannabinoids structurally related to THC. THCP is not explicitly named[16] |
| Sweden | Narcotic | Classified as a narcotic substance effective July 11, 2023[6] |
| Switzerland | Banned | THCP and related dibenzopyran-structure cannabinoids banned October 2023[3] |
| France | Banned | Banned in 2024[16] |
| Czech Republic | Controlled | Added to controlled substances list in early 2024[16] |
| Spain | Schedule II | Added to Schedule II in April 2025[16] |
| Denmark | Not explicitly banned (as of 2024) | HHC scheduling in May 2023 shifted market dynamics but THCP was not explicitly controlled during the study period[17] |
| Canada | Likely controlled (CDSA Schedule II) | THC analogues are controlled under the Controlled Drugs and Substances Act. THCP as a THC homolog is likely controlled, but explicit naming has not been confirmedcitation needed |
| Australia | Likely Schedule 9 (Poisons Standard) | Expected to be controlled as a THC analogue, but THCP has not been found explicitly named in a published scheduling decisioncitation needed |
Legal status changes frequently and varies by jurisdiction. This information may be outdated. Nothing here constitutes legal advice.
references
- [1] ^abcdefghCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [2]
- [3]
- [4]
- [5] ^abcJanssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP (2024) Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugs — Archives of Toxicology doi:10.1007/s00204-024-03769-4
- [6] ^abcHelander A, Johansson M, Villén T, Andersson A (2024) Appearance of hexahydrocannabinols as recreational drugs and implications for cannabis drug testing - focus on HHC, HHC-P, HHC-O and HHC-H — Scandinavian Journal of Clinical and Laboratory Investigation doi:10.1080/00365513.2024.2340039